Altimmune prices $75 million stock offering to fund MASH trial

Altimmune Inc. (NASDAQ: ALT) announced it has entered into a securities purchase agreement for a registered direct offering of 17,045,454 shares of common stock and pre-funded warrants, according to a company statement.

The biopharmaceutical company expects to receive gross proceeds of approximately $75 million before deducting placement agent fees and other offering expenses. The offering involves a new fundamental institutional investor and is expected to close on or about January 29, 2026, subject to customary closing conditions.

Altimmune stated it intends to use the net proceeds to fund preparation for its upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH) as well as for working capital and general corporate purposes. The company's lead candidate, pemvidutide, is a glucagon/GLP-1 dual agonist that received Breakthrough Therapy Designation from the U.S. FDA.

Titan Partners, a division of American Capital Partners, is serving as the sole placement agent for the offering. The securities are being offered pursuant to an effective shelf registration statement that was declared effective by the Securities and Exchange Commission on December 5, 2025.

The Gaithersburg, Maryland-based company develops therapies targeting serious liver diseases. Pemvidutide is being developed for treatment of MASH, alcohol use disorder, and alcohol-associated liver disease.

You May Also Be Interested In

• Bluerock Acquisition Corp. II closes $172.5M IPO on Nasdaq
• Surf Air Mobility names Jason Secore as CFO, effective Sept. 30
• AtlasClear insiders buy 815,000 shares for roughly $162,500